|
1
|
No authors listed. Interferon-alpha and
survival in metastatic renal carcinoma: early results of a
randomised controlled trial. Medical Research Council Renal Cancer
Collaborators. Lancet. 353:14–17. 1999.
|
|
2
|
Yang JC, Sherry RM, Steinberg SM, Topalian
SL, Schwartzentruber DJ, Hwu P, et al: Randomized study of
high-dose and low-dose interleukin-2 in patients with metastatic
renal cancer. J Clin Oncol. 21:3127–3132. 2003.
|
|
3
|
McDermott DF, Regan MM, Clark JI, Flaherty
LE, Weiss GR, Logan TF, et al: Randomized phase III trial of
high-dose interleukin-2 versus subcutaneous interleukin-2 and
interferon in patients with metastatic renal cell carcinoma. J Clin
Oncol. 23:133–141. 2005.
|
|
4
|
Rini BI, Halabi S, Rosenberg JE, Stadler
WM, Vaena DA, Archer L, et al: Phase III trial of bevacizumab plus
interferon alfa versus interferon alfa monotherapy in patients with
metastatic renal cell carcinoma: final results of CALGB 90206. J
Clin Oncol. 28:2137–2143. 2010.
|
|
5
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Staehler M, et al: Sorafenib for treatment of renal
cell carcinoma: Final efficacy and safety results of the phase III
treatment approaches in renal cancer global evaluation trial. J
Clin Oncol. 27:3312–3318. 2009.
|
|
6
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, et al: Overall survival and
updated results for sunitinib compared with interferon alfa in
patients with metastatic renal cell carcinoma. J Clin Oncol.
27:3584–3590. 2009.
|
|
7
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, et al: Comparative effectiveness of axitinib
versus sorafenib in advanced renal cell carcinoma (AXIS): a
randomised phase 3 trial. Lancet. 378:1931–1939. 2011.
|
|
8
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, et al: Pazopanib in locally advanced
or metastatic renal cell carcinoma: results of a randomized phase
III trial. J Clin Oncol. 28:1061–1068. 2010.
|
|
9
|
Horsley L, Marti K and Jayson GC: Is the
toxicity of anti-angiogenic drugs predictive of outcome? A review
of hypertension and proteinuria as biomarkers of response to
anti-angiogenic therapy. Expert Opin Drug Metab Toxicol. 8:283–293.
2012.
|
|
10
|
National Cancer Institute. Common
Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE).
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm.
Accessed March 14, 2014
|
|
11
|
Tomita Y, Uemura H, Fujimoto H, Kanayama
HO, Shinohara N, Nakazawa H, et al; Japan Axitinib Phase II Study
Group. Key predictive factors of axitinib (AG-013736)-induced
proteinuria and efficacy: a phase II study in Japanese patients
with cytokine-refractory metastatic renal cell Carcinoma. Eur J
Cancer. 47:2592–2602. 2011.
|
|
12
|
Goodwin R, Ding K, Seymour L, LeMaître A,
Arnold A, Shepherd FA, et al; NCIC Clinical Trials Group.
Treatment-emergent hypertension and outcomes in patients with
advanced non-small-cell lung cancer receiving chemotherapy with or
without the vascular endothelial growth factor receptor inhibitor
cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol.
21:2220–2226. 2010.
|
|
13
|
Zhu X, Stergiopoulos K and Wu S: Risk of
hypertension and renal dysfunction with an angiogenesis inhibitor
sunitinib: systematic review and meta-analysis. Acta Oncol.
48:9–17. 2009.
|
|
14
|
Larochelle P, Kollmannsberger C, Feldman
RD, Schiffrin EL, Poirier L, Patenaude F, et al: Hypertension
management in patients with renal cell cancer treated with
anti-angiogenic agents. Curr Oncol. 19:202–208. 2012.
|
|
15
|
Maitland ML, Bakris GL, Black HR, Chen HX,
Durand JB, Elliott WJ, et al; Cardiovascular Toxicities Panel,
Convened by the Angiogenesis Task Force of the National Cancer
Institute Investigational Drug Steering Committee. Initial
assessment, surveillance, and management of blood pressure in
patients receiving vascular endothelial growth factor signaling
pathway inhibitors. J Natl Cancer Inst. 102:596–604. 2010.
|
|
16
|
Izzedine H, Ederhy S, Goldwasser F, Soria
JC, Milano G, Cohen A, et al: Management of hypertension in
angiogenesis inhibitor-treated patients. Ann Oncol. 20:807–815.
2009.
|
|
17
|
Miyajima A, Kikuchi E, Kosaka T and Oya M:
Angiotensin II type 1 receptor antagonist as an angiogenic
inhibitor in urogenital cancer. Rev Recent Clin Trials. 4:75–78.
2009.
|
|
18
|
Mc Menamin ÚC, Murray LJ, Cantwell MM and
Hughes CM: Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in cancer progression and survival: a systematic
review. Cancer Causes Control. 23:221–230. 2012.
|
|
19
|
Julius S, Kjeldsen SE, Weber M, Brunner
HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in
hypertensive patients at high cardiovascular risk treated with
regimens based on valsartan or amlodipine: the VALUE randomised
trial. Lancet. 363:2022–2031. 2004.
|
|
20
|
Lindholm LH, Ibsen H, Dahlöf B, Devereux
RB, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular
morbidity and mortality in patients with diabetes in the Losartan
Intervention For Endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet. 359:1004–1010. 2002.
|
